- Home
- EOI vs AUTL Comparison
EOI vs AUTL Comparison
Compare EOI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- AUTL
- Stock Information
- Founded
- EOI 2004
- AUTL 2014
- Country
- EOI United States
- AUTL United Kingdom
- Employees
- EOI N/A
- AUTL N/A
- Industry
- EOI Finance/Investors Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EOI Finance
- AUTL Health Care
- Exchange
- EOI Nasdaq
- AUTL Nasdaq
- Market Cap
- EOI 819.4M
- AUTL 625.4M
- IPO Year
- EOI N/A
- AUTL 2018
- Fundamental
- Price
- EOI $20.83
- AUTL $2.49
- Analyst Decision
- EOI
- AUTL Strong Buy
- Analyst Count
- EOI 0
- AUTL 5
- Target Price
- EOI N/A
- AUTL $9.32
- AVG Volume (30 Days)
- EOI 83.6K
- AUTL 1.7M
- Earning Date
- EOI 01-01-0001
- AUTL 08-07-2025
- Dividend Yield
- EOI 7.19%
- AUTL N/A
- EPS Growth
- EOI N/A
- AUTL N/A
- EPS
- EOI N/A
- AUTL N/A
- Revenue
- EOI N/A
- AUTL $9,011,000.00
- Revenue This Year
- EOI N/A
- AUTL $461.76
- Revenue Next Year
- EOI N/A
- AUTL $112.66
- P/E Ratio
- EOI N/A
- AUTL N/A
- Revenue Growth
- EOI N/A
- AUTL N/A
- 52 Week Low
- EOI $14.36
- AUTL $1.11
- 52 Week High
- EOI $18.88
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- EOI 60.48
- AUTL 73.68
- Support Level
- EOI $20.80
- AUTL $2.40
- Resistance Level
- EOI $21.00
- AUTL $2.53
- Average True Range (ATR)
- EOI 0.19
- AUTL 0.13
- MACD
- EOI -0.02
- AUTL 0.01
- Stochastic Oscillator
- EOI 72.22
- AUTL 89.80
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.